← All trials
NCT06461026
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 19, 2024
- Primary completion
- Aug 31, 2025
- Completion date
- Aug 31, 2025
- First posted
- Jun 14, 2024
- Last posted
- Aug 28, 2024
- Enrollment
- 180
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- Indiana UniversityCollaborator
- University of WashingtonCollaborator
- National Institutes of Health (NIH)Collaborator
- Harvard UniversityCollaborator
- National Institutes of Health (NIH)Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.